Open AccessA severe infective endocarditis successfully treated with linezolid
Author(s) -
Graziano Antonio Minafra,
Donatella Cibelli,
M. Pipino,
Vincenzo Dargenio,
Francesco Ventrella
Publication year - 2010
Publication title -
clinical management issues
Language(s) - English
Resource type - Journals
eISSN - 2283-3137
pISSN - 1973-4832
DOI - 10.7175/cmi.v4i1.538
Subject(s) - linezolid , medicine , endocarditis , infective endocarditis , pneumonia , antibiotics , surgery , streptococcus bovis , microbiology and biotechnology , staphylococcus aureus , vancomycin , bacteria , rumen , chemistry , food science , biology , fermentation , genetics
Despite significant improvements in surgical and medical therapy, prosthetic valve endocarditis (PVE) is a diagnostic and therapeutic challenge and is often associated with a severe prognosis. We report a case of a 59-year-old woman, with PVE and bacterial endocarditis (Streptococcus bovis) successfully treated with linezolid. Linezolid is a bacteriostatic oxazolidinone antibiotic that has been proven to be effective for the treatment of patients with pneumonia, skin and soft tissue infections, and infections due to Gram-positive cocci. Linezolid is not yet recognised as a standard therapy for infective endocarditis, but its use becomes a necessity when infection is due to multidrug-resistant microorganisms